Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration ("FDA") has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid ("HA") gel, the latest addition to the Obagi® injectable portfolio under the Obagi Medical brand.

This approval builds on the launch of Obagi® saypha® MagIQ™ and accelerates Obagi Medical's strategy to establish Obagi as a comprehensive leader at the intersection of advanced skincare and medical aesthetics. The introduction of Obagi® saypha® ChIQ™ further expands the brand's addressable market in the fast-growing U.S. dermal filler category.